129 related articles for article (PubMed ID: 22475604)
1. Pertuzumab plus trastuzumab in metastatic breast cancer.
Revannasiddaiah S; Seam R; Gupta M
N Engl J Med; 2012 Apr; 366(14):1349; author reply 1349-50. PubMed ID: 22475604
[No Abstract] [Full Text] [Related]
2. Pertuzumab plus trastuzumab in metastatic breast cancer.
Li-Wan-Po A
N Engl J Med; 2012 Apr; 366(14):1348-9; author reply 1349-50. PubMed ID: 22475603
[No Abstract] [Full Text] [Related]
3. Pertuzumab plus trastuzumab in metastatic breast cancer.
Şendur MA; Aksoy S; Zengin N
N Engl J Med; 2012 Apr; 366(14):1348; author reply 1349-50. PubMed ID: 22475602
[No Abstract] [Full Text] [Related]
4. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
[No Abstract] [Full Text] [Related]
5. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
6. [Pertuzumab+trastuzumab+DTX therapy].
Maejima A; Tamura K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():553-7. PubMed ID: 25831821
[No Abstract] [Full Text] [Related]
7. CLEOPATRA holds strong in final analysis.
Cancer Discov; 2014 Dec; 4(12):OF3. PubMed ID: 25477120
[TBL] [Abstract][Full Text] [Related]
8. HER2 therapy--an abundance of riches.
Gradishar WJ
N Engl J Med; 2012 Jan; 366(2):176-8. PubMed ID: 22149874
[No Abstract] [Full Text] [Related]
9. Dual HER2 blockade slows metastatic breast cancer.
Bender E
Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
11. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
13. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
Dao BD; Ho H; Quintal LN
J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
[TBL] [Abstract][Full Text] [Related]
14. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
15. The beautiful history of pertuzumab.
Perez-Garcia J; Muñoz-Couselo E; Ortega V; Cortes J
Expert Rev Anticancer Ther; 2012 Jun; 12(6):703-5. PubMed ID: 22716485
[No Abstract] [Full Text] [Related]
16. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Abair T; O'Shaughnessy J
Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
[No Abstract] [Full Text] [Related]
19. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
